Abstract
This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N=398) and subsequent open-label extension. Patients were followed for up to 6.5 years with a mean of 3.5 ± 2.1 years. After 12 months, additional PD medications were added as required. Of patients remaining in the trial at 2 years, 46% were maintained on rasagiline monotherapy. The majority of patients received a dopamine agonist prior to levodopa as the first additional dopaminergic agent. Analysis using a Kaplan-Meier method indicated that by 5.4 years only 25 of patients progressed to Hoehn & Yahr stage III. Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.
Original language | English (US) |
---|---|
Pages (from-to) | 404-408 |
Number of pages | 5 |
Journal | International Journal of Neuroscience |
Volume | 120 |
Issue number | 6 |
DOIs | |
State | Published - May 2010 |
Keywords
- Dopamine agonists
- Efficacy
- Levodopa
- Long-term
- Monotherapy
- Rasagiline
ASJC Scopus subject areas
- Neuroscience(all)